Authored by Aldgra Fredly via The Epoch Times,

President Donald Trump announced on May 1 that Medicare patients will soon be able to obtain coverage for weight-loss drugs for $50 per month.

Speaking at an event in Florida, Trump said the coverage for the weight-loss and diabetes medications will begin in July, referencing drugs that contain semaglutide, a GLP-1 receptor agonist.

“Today, I’m thrilled to announce that starting on July 1, we will also provide Medicare patients with the coverage for weight-loss drugs like Ozempic, Zepbound, Wegovy. Will be available for $50 a month,” he said.

In December, the Centers for Medicare & Medicaid Services (CMS) announced a voluntary model known as Better Approaches to Lifestyle and Nutrition for Comprehensive Health to expand access to GLP-1 medications for weight management and metabolic health, allowing Medicare Part D plans and state Medicaid agencies to cover the drugs while negotiating lower prices.

The model features CMS negotiating directly with manufacturers for reduced net prices, out-of-pocket caps, standardized coverage criteria, and lifestyle support programs.